Stryker Co. (NYSE:SYK) Stock Holdings Lifted by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC raised its stake in Stryker Co. (NYSE:SYK) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 88,310 shares of the medical technology company’s stock after purchasing an additional 1,419 shares during the quarter. Stryker accounts for 3.9% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 4th biggest holding. LaFleur & Godfrey LLC’s holdings in Stryker were worth $26,445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Freedom Wealth Alliance LLC acquired a new stake in Stryker in the fourth quarter valued at $26,000. Quarry LP acquired a new position in shares of Stryker during the 1st quarter worth $27,000. Rise Advisors LLC raised its stake in shares of Stryker by 692.9% during the 3rd quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. West Tower Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth $35,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth $38,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 0.0 %

Shares of NYSE:SYK traded down $0.14 during trading on Thursday, reaching $358.57. 381,472 shares of the stock were exchanged, compared to its average volume of 1,312,687. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The firm has a market cap of $136.24 billion, a price-to-earnings ratio of 43.15, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89. The firm’s 50-day moving average price is $342.51 and its 200 day moving average price is $305.23.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the company posted $3.00 EPS. Stryker’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 38.79%.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last 90 days. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their price target for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Truist Financial lifted their price target on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Citigroup lifted their price target on Stryker from $340.00 to $362.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Roth Mkm lifted their price objective on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $331.52.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.